烟台论坛-烟台社区

标题: 辉瑞的官方回应，自己看吧~ [打印本页]

作者: lvjingyi123456 时间: 2023-1-29 15:35
标题: 辉瑞的官方回应，自己看吧~
Science
Products
2Pfizer
Pfizer Responds to Research Claims
Stories
Newsroom
About
Q
Contact Us
Friday, January 27, 2023 -08:00pm
New York, N.Y., January 27, 2023 - Allegations have recently been made related to gain of function and directed evolution
research at Pfizer and the company would like to set the record straight.
In the ongoing development of the Pfizer-BioNTech COVID-19 vaccine, Pfizer has not conducted gain of function or directed evolution research. Working with collaborators, we have conducted research where the original SARS-CoV-2 virus has been used to express the spike protein from new variants of concern. This work is undertaken once a new variant of concern has been identified by public health authorities. This research provides a way for us to rapidly assess the ability of an existing vaccine to induce antibodies that neutralize a newly identified variant of concern. We then make this data available through peer reviewed scientific journals and use it as one of the steps to determine whether a
vaccine update is required.
In addition, to meet U.S. and global regulatory requirements for our oral treatment, PAXLOVID~", Pfizer undertakes in vitro work (e.g., in a laboratory culture dish) to identify potential resistance mutations to nirmatrelvir, one of PAXLOVID'S two components. With a naturally evolving virus, it is important to routinely assess the activity of an antiviral. Most of this work is conducted using computer simulations or mutations of the main protease-a non-infectious part of the virus.In a limited number of cases when a full virus does not contain any known gain of function mutations, such virus may be engineered to enable the assessment of antiviral activity in cells. In addition, in vitro resistance selection experiments are undertaken in cells incubated with SARS-CoV-2 and nirmatrelvir in our secure Biosafety level 3 (BSL3) laboratory to assess whether the main protease can mutate to yield resistant strains of the virus. It is important to note that these studies are required by U.S. and global regulators for all antiviral products and are carried out by many companies and academic institutions in the U.S. and around the world.
Fact-based information rooted in sound science is vitally important to overcoming the COVID-19 pandemic and Pfizer
remains committed to transparency and helping alleviate the devastating burden of this disease.

自己看吧~反正是大体意思就是没否认在研究，但研究是为了更好的开发药物~

作者: lvjingyi123456 时间: 2023-1-30 16:00
研究是研究了，但是为啥研究的就不好说了~

作者: SE图哥 时间: 2023-1-30 16:06
twitter上这个视频已经删的干干净净，只有一些铁杆*华还揪着里面一句话，大肆宣传病毒是武汉制造的

作者: lvjingyi123456 时间: 2023-1-30 16:08

SE图哥发表于 2023-1-30 16:06
twitter上这个视频已经删的干干净净，只有一些铁杆*华还揪着里面一句话，大肆宣传病毒是武汉制造的

十有八九都是小润人和小殖人~

作者: 牛家卧 时间: 2023-1-30 16:20
生化危机里面的那个什么保护伞公司？？哈哈哈

作者: Schnheit 时间: 2023-1-30 16:53
提示: 作者被禁止或删除内容自动屏蔽

作者: csasd 时间: 2023-1-30 17:46
大体意思是辉瑞承认的确在实验室制造变异毒株，但目的是为了研究药物而已，辉瑞需要确定病毒对paxlovid的潜在耐药突变，并强调这符合美国监管机构的要求。

作者: gudiehu 时间: 2023-1-30 19:12

csasd 发表于 2023-1-30 17:46
大体意思是辉瑞承认的确在实验室制造变异毒株，但目的是为了研究药物而已，辉瑞需要确定病毒对paxlovid的潜 ...

没看出来那句话说的制造变异毒株，请标示出来。

作者: 善待自己和他人 时间: 2023-1-30 19:19
论坛英语过硬的
给美丽国洗地的
为辉瑞开脱的进来说说

作者: 心想事成2023 时间: 2023-1-30 19:21
提示: 作者被禁止或删除内容自动屏蔽

作者: lvjingyi123456 时间: 2023-1-31 10:48

gudiehu 发表于 2023-1-30 19:12
没看出来那句话说的制造变异毒株，请标示出来。

In addition, in vitro resistance selection experiments are undertaken in cells incubated with SARS-CoV-2 and nirmatrelvir in our secure Biosafety level 3 (BSL3) laboratory to assess whether the main protease can mutate to yield resistant strains of the virus.

这个说制造不太对，算是寻找吧~

欢迎光临烟台论坛-烟台社区 (https://www.ytbbs.com/)